Cystic fibrosis is an autosomal recessive disorder that causes non-functional CFTR proteins, which prevents the transport of chloride ions from the interior of epithelial cells to the air-liquid interface in the lungs, resulting in the accumulation of thick mucus that reduces breath capacity and gas exchange. Gene editing platforms have been developed to address the source of the mutations in the genome, and nucleic acid-containing lipid nanoparticles (LNPs) offer a promising new platform due to their previous approval, ability to encapsulate various cargoes, and high modularity in targeting specific organs, like the lungs. This work focuses on the creation of LNPs delivering Cas9 for CRISPR-Cas9 gene editing as protein or mRNA, and comparing the efficacy and functional repair between the two. LNP formulations were identified for CRISPR gene editing for corrective editing, and these LNPs with protein or mRNA Cas9 were evaluated for the tropism in the body when delivered intravenously. These formulations were screened for editing potential in vivo, and then screened in vitro for their corrective editing potential for the f508del cystic fibrosis mutation. Protein Cas9 formulations exhibited similar lung tropism as mRNA formulations, but were able to perform higher levels of functional editing in vitro and in vivo. Further work will be done to evaluate the top performers’ ability to restore CFTR function in CFTR-focused assays.